# Philip N Hawkins

## List of Publications by Year in Descending Order

**Source:** https://exaly.com/author-pdf/5738097/philip-n-hawkins-publications-by-year.pdf
**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|---|---|---|---|
| 101 papers | 10,300 citations | 40 h-index | 101 g-index |
| 111 ext. papers | 12,408 ext. citations | 7.4 avg, IF | 5.85 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 101 | Cardiac Magnetic Resonance-Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. *Circulation: Cardiovascular Imaging*, **2021**, CIRCIMAGING121012506 | 3.9 | 7 |
| 100 | Search for AL amyloidosis risk factors using Mendelian randomization. *Blood Advances*, **2021**, 5, 2725-2731 | 7.18 | 3 |
| 99 | 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 1304-1311 | 4.1 | 6 |
| 98 | Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 273-281 | 4.1 | 3 |
| 97 | Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. *European Heart Journal*, **2021**, | 9.5 | 9 |
| 96 | Two types of systemic amyloidosis in a single patient. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **2020**, 27, 275-276 | 2.7 | 3 |
| 95 | Diagnostic imaging of cardiac amyloidosis. *Nature Reviews Cardiology*, **2020**, 17, 413-426 | 14.8 | 39 |
| 94 | Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. *European Heart Journal*, **2020**, 41, 1439-1447 | 9.5 | 50 |
| 93 | The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. *Blood*, **2020**, 136, 40-40 | 2.2 | 1 |
| 92 | TRAP1 chaperone protein mutations and autoinflammation. *Life Science Alliance*, **2020**, 3, | 5.8 | 7 |
| 91 | Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. *JACC: Cardiovascular Imaging*, **2020**, 13, 2546-2557 | 8.4 | 7 |
| 90 | Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. *Leukemia*, **2020**, 34, 1187-1191 | 10.7 | 12 |
| 89 | Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. *Journal of the American Heart Association*, **2019**, 8, e012097 | 6 | 14 |
| 88 | A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. *Blood*, **2019**, 134, 2271-2280 | 2.2 | 77 |
| 87 | The UK National Amyloidosis Centre. *European Heart Journal*, **2019**, 40, 1661-1664 | 9.5 | 1 |
| 86 | Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. *Scientific Reports*, **2019**, 9, 1388 | 4.9 | 15 |
| 85 | Recognising and understanding cryopyrin-associated periodic syndrome in adults. *British Journal of Nursing*, **2019**, 28, 1180-1186 | 0.7 | 3 |

| | | | |
|---|---|---|---|
| 84 | Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction: Validation Against Invasive Coronary Physiology. *JACC: Cardiovascular Imaging*, **2019**, 12, 1958-1969 | 8.4 | 66 |
| 83 | Native T1 and Extracellular Volume in Transthyretin Amyloidosis. *JACC: Cardiovascular Imaging*, **2019**, 12, 810-819 | 8.4 | 89 |
| 82 | Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. *JACC: Cardiovascular Imaging*, **2019**, 12, 823-833 | 8.4 | 55 |
| 81 | Role of Tc-DPD scintigraphy in imaging extra-cardiac light chain (AL) amyloidosis. *British Journal of Haematology*, **2018**, 183, 506-509 | 4.5 | 3 |
| 80 | Systemic immunoglobulin light chain amyloidosis. *Nature Reviews Disease Primers*, **2018**, 4, 38 | 51.1 | 207 |
| 79 | Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue-a case series and genetic exploration. *Rheumatology*, **2017**, 56, 209-213 | 3.9 | 38 |
| 78 | High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. *Sleep Medicine*, **2017**, 32, 191-197 | 4.6 | 3 |
| 77 | Six-minute walk test (6MWT) in AL amyloidosis - baseline and 12-month follow-up after chemotherapy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 62-63 | 2.7 | 3 |
| 76 | A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 72-73 | 2.7 | 1 |
| 75 | Hyperimmunoglobulin D syndrome in an Indian family undiagnosed for 11 years. *International Journal of Rheumatic Diseases*, **2017**, 20, 2236-2237 | 2.3 | 1 |
| 74 | International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. *Rheumatology*, **2017**, 56, 2102-2108 | 3.9 | 54 |
| 73 | Magnetic Resonance in Transthyretin Cardiac Amyloidosis. *Journal of the American College of Cardiology*, **2017**, 70, 466-477 | 15.1 | 176 |
| 72 | 001 Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. *Heart*, **2017**, 103, A1-A2 | 5.1 | 11 |
| 71 | Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. *Haematologica*, **2017**, 102, e411-e414 | 6.6 | 7 |
| 70 | European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. *Journal of Clinical Oncology*, **2016**, 34, 2037-45 | 2.2 | 46 |
| 69 | EULAR recommendations for the management of familial Mediterranean fever. *Annals of the Rheumatic Diseases*, **2016**, 75, 644-51 | 2.4 | 241 |
| 68 | Systemic amyloidosis. *Lancet, The*, **2016**, 387, 2641-2654 | 40 | 475 |
| 67 | Comparison of Free Light Chain Assays: Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis. *American Journal of Clinical Pathology*, **2016**, 146, 78-85 | 1.9 | 7 |

| | | | |
|---|---|---|---|
| 66 | Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*, **2016**, 133, 2404-12 | 16.7 | 792 |
| 65 | Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. *New England Journal of Medicine*, **2015**, 373, 1106-14 | 59.2 | 250 |
| 64 | Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. *Lancet Haematology,the*, **2015**, 2, e241-50 | 14.6 | 76 |
| 63 | Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. *Circulation*, **2015**, 132, 1570-9 | 16.7 | 320 |
| 62 | Emerging treatments for amyloidosis. *Kidney International*, **2015**, 87, 516-26 | 9.9 | 20 |
| 61 | A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood*, **2015**, 126, 612-5 | 2.2 | 232 |
| 60 | T1 mapping and survival in systemic light-chain amyloidosis. *European Heart Journal*, **2015**, 36, 244-51 | 9.5 | 247 |
| 59 | CMR-based differentiation of AL and ATTR cardiac amyloidosis. *JACC: Cardiovascular Imaging*, **2014**, 7, 133-42 | 8.4 | 182 |
| 58 | Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. *Haematologica*, **2014**, 99, e260-3 | 6.6 | 11 |
| 57 | Two types of amyloid in a single heart. *Blood*, **2014**, 124, 3025-7 | 2.2 | 20 |
| 56 | Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). *Haematologica*, **2014**, 99, 1479-85 | 6.6 | 83 |
| 55 | Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 1289-98 | 4.1 | 131 |
| 54 | Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. *Human Mutation*, **2014**, 35, E2403-12 | 4.7 | 162 |
| 53 | Native T1 mapping in transthyretin amyloidosis. *JACC: Cardiovascular Imaging*, **2014**, 7, 157-65 | 8.4 | 265 |
| 52 | The Prognostic Significance of Phenotypically Normal Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma. *Blood*, **2014**, 124, 2073-2073 | 2.2 | 1 |
| 51 | Acute hepatitis in a child heterozygous for the I259V MEFV gene variant. *Prague Medical Report*, **2014**, 115, 128-33 | 0.7 | 3 |
| 50 | A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis. *Blood*, **2014**, 124, 305-305 | 2.2 | |
| 49 | Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD). *Blood*, **2014**, 124, 1198-1198 | 2.2 | |

| | | | |
|---|---|---|---|
| 48 | Measurement of Tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced MR imaging. *Radiology*, **2013**, 268, 858-64 | 20.5 | 40 |
| 47 | A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. *Blood*, **2013**, 121, 3420-7 | 2.2 | 267 |
| 46 | New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *Journal of Clinical Oncology*, **2012**, 30, 4541-9 | 2.2 | 553 |
| 45 | A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.. *Blood*, **2012**, 120, 2966-2966 | 2.2 | 1 |
| 44 | Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.. *Blood*, **2012**, 120, 2978-2978 | 2.2 | |
| 43 | Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. *Blood*, **2012**, 120, 4074-4074 | 2.2 | 1 |
| 42 | A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. *Journal of Cardiology Cases*, **2011**, 4, e93-e97 | 0.6 | 24 |
| 41 | ALchemy - A Large Prospective Real World' Study of Chemotherapy in AL Amyloidosis. *Blood*, **2011**, 118, 992-992 | 2.2 | 4 |
| 40 | European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. *Blood*, **2011**, 118, 995-995 | 2.2 | 3 |
| 39 | Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,. *Blood*, **2011**, 118, 3975-3975 | 2.2 | 1 |
| 38 | Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,. *Blood*, **2011**, 118, 3978-3978 | 2.2 | 0 |
| 37 | Validation of the Criteria of Response to Treatment In AL Amyloidosis.. *Blood*, **2010**, 116, 1364-1364 | 2.2 | 15 |
| 36 | A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. *Blood*, **2010**, 116, 988-988 | 2.2 | 4 |
| 35 | Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases. *Blood*, **2010**, 116, 3958-3958 | 2.2 | |
| 34 | Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment.. *Blood*, **2009**, 114, 1791-1791 | 2.2 | 3 |
| 33 | A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.. *Blood*, **2009**, 114, 2796-2796 | 2.2 | 6 |
| 32 | Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis Results From the UK Amyloidosis Treatment Trial.. *Blood*, **2009**, 114, 2869-2869 | 2.2 | 10 |
| 31 | In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. *Blood*, **2009**, 114, 745-745 | 2.2 | 6 |

| | | | |
|---|---|---|---|
| 30 | Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.. *Blood*, **2009**, 114, 2814-2814 | 2.2 | |
| 29 | Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.. *Blood*, **2009**, 114, 1863-1863 | 2.2 | |
| 28 | Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. *Blood*, **2008**, 112, 1689-1689 | 2.2 | 3 |
| 27 | Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. *Blood*, **2008**, 112, 1733-1733 | 2.2 | 1 |
| 26 | Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. *Blood*, **2008**, 112, 869-869 | 2.2 | 4 |
| 25 | Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. *American Journal of Medicine*, **2006**, 119, 355.e15-24 | 2.4 | 101 |
| 24 | Systemic amyloidosis. *Current Opinion in Pharmacology*, **2006**, 6, 214-20 | 5.1 | 73 |
| 23 | Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. *British Journal of Haematology*, **2006**, 134, 417-25 | 4.5 | 72 |
| 22 | Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. *Blood*, **2006**, 108, 129-129 | 2.2 | 8 |
| 21 | Superior mesenteric artery syndrome in a young girl following spinal surgery for scoliosis. *British Journal of Hospital Medicine (London, England: 2005)*, **2005**, 66, 700-1 | 0.8 | |
| 20 | Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. *American Journal of Hematology*, **2005**, 79, 319-28 | 7.1 | 971 |
| 19 | Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. *Blood*, **2005**, 106, 3495-3495 | 2.2 | 2 |
| 18 | Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. *Arthritis and Rheumatism*, **2004**, 50, 607-12 | | 650 |
| 17 | Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis.. *Blood*, **2004**, 104, 755-755 | 2.2 | 5 |
| 16 | Impact of Chromosomal Abnormalities Revealed by Interphase FISH on Survival in Primary Light Chain Amyloidosis.. *Blood*, **2004**, 104, 4875-4875 | 2.2 | |
| 15 | Hereditary systemic amyloidosis with renal involvement. *Journal of Nephrology*, **2003**, 16, 443-8 | 4.8 | 29 |
| 14 | Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. *New England Journal of Medicine*, **2002**, 346, 1786-91 | 59.2 | 516 |
| 13 | Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. *Current Opinion in Nephrology and Hypertension*, **2002**, 11, 649-55 | 3.5 | 108 |

| | | | |
|---|---|---|---|
| 12 | An autosomal dominant periodic fever associated with AA amyloidosis in a north Indian family maps to distal chromosome 1q. *Arthritis and Rheumatism*, **2000**, 43, 2034-40 | | 37 |
| 11 | Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. *British Journal of Haematology*, **2000**, 110, 454-60 | 4.5 | 155 |
| 10 | Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. *European Journal of Nuclear Medicine and Molecular Imaging*, **1998**, 25, 709-13 | 8.8 | 57 |
| 9 | Allogeneic bone marrow transplantation for systemic AL amyloidosis. *British Journal of Haematology*, **1998**, 100, 226-8 | 4.5 | 45 |
| 8 | SAA1 alleles as risk factors in reactive systemic AA amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **1998**, 5, 262-5 | 2.7 | 84 |
| 7 | Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. *Nature*, **1997**, 385, 787-93 | 50.4 | 980 |
| 6 | Amyloidosis: a review of recent diagnostic and therapeutic developments. *British Journal of Haematology*, **1997**, 99, 245-56 | 4.5 | 143 |
| 5 | Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1995**, 2, 163-166 | 2.7 | 7 |
| 4 | Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. *Clinical Science*, **1994**, 87, 289-95 | 6.5 | 70 |
| 3 | Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). *Clinical Genetics*, **1991**, 40, 242-6 | 4 | 278 |
| 2 | Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. *New England Journal of Medicine*, **1990**, 323, 508-13 | 59.2 | 422 |
| 1 | Systemic Amyloidosis886-892 | | |